Details

Autor(en) / Beteiligte

• Ohtsuki, Tomohiro
• Satoh, Kimio
• Omura, Junichi
• Kikuchi, Nobuhiro
• Satoh, Taijyu
• Kurosawa, Ryo
• Nogi, Masamichi
• Sunamura, Shinichiro
• Yaoita, Nobuhiro
• Aoki, Tatsuo
• Tatebe, Shunsuke
• Sugimura, Koichiro
• Takahashi, Jun
• Miyata, Satoshi
• Shimokawa, Hiroaki

Titel

Prognostic Impacts of Plasma Levels of Cyclophilin A in Patients With Coronary Artery Disease

Ist Teil von

• Arteriosclerosis, thrombosis, and vascular biology, 2017-04, Vol.37 (4), p.685-693

Ort / Verlag

United States

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Cyclophilin A (CyPA) is secreted from vascular smooth muscle cells, inflammatory cells, and activated platelets in response to oxidative stress. We have recently demonstrated that plasma CyPA level is a novel biomarker for diagnosing coronary artery disease. However, it remains to be elucidated whether plasma CyPA levels also have a prognostic impact in such patients. In 511 consecutive patients undergoing diagnostic coronary angiography, we measured the plasma levels of CyPA, high-sensitivity C-reactive protein (hsCRP), and brain natriuretic peptide and evaluated their prognostic impacts during the follow-up (42 months, interquartile range: 25-55 months). Higher CyPA levels (≥12 ng/mL) were significantly associated with all-cause death, rehospitalization, and coronary revascularization. Higher hsCRP levels (≥1 mg/L) were also significantly correlated with the primary end point and all-cause death, but not with rehospitalization or coronary revascularization. Similarly, higher brain natriuretic peptide levels (≥100 pg/mL) were significantly associated with all-cause death and rehospitalization, but not with coronary revascularization. Importantly, the combination of CyPA (≥12 ng/mL) and hsCRP (≥1 mg/L) was more significantly associated with all-cause death (hazard ratio, 21.2; 95% confidence interval, 4.9-92.3,; <0.001) than CyPA (≥12 ng/mL) or hsCRP (≥1 mg/L) alone. The results indicate that plasma CyPA levels can be used to predict all-cause death, rehospitalization, and coronary revascularization in patients with coronary artery disease and that when combined with other biomarkers (hsCRP and brain natriuretic peptide levels), the CyPA levels have further enhanced prognostic impacts in those patients.